We demonstrated for the first time that the combination of a novel 4-thiazolidinone derivative (Les-4367) with anti-HER2 antibodies (trastuzumab and pertuzumab) is a promising anticancer strategy in AGS gastric cancer cells. This evidence concerns the gene ERBB2 and gastric cancer.